Log in

OTCMKTS:RLMDRelmada Therapeutics Stock Price, Forecast & News

+0.01 (+0.02 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $42.33
50-Day Range
MA: $46.40
52-Week Range
Now: $42.33
Volume96,600 shs
Average Volume168,785 shs
Market Capitalization$643.33 million
P/E RatioN/A
Dividend YieldN/A
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Current SymbolOTCMKTS:RLMD



Sales & Book Value

Annual SalesN/A



Market Cap$643.33 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions

How has Relmada Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RLMD shares have increased by 5.3% and is now trading at $42.33. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Relmada Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Relmada Therapeutics.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics Inc (OTCMKTS:RLMD) announced its earnings results on Tuesday, November, 13th. The company reported ($0.27) EPS for the quarter. View Relmada Therapeutics' earnings history.

What price target have analysts set for RLMD?

4 Wall Street analysts have issued 12-month price objectives for Relmada Therapeutics' shares. Their forecasts range from $63.00 to $75.00. On average, they anticipate Relmada Therapeutics' stock price to reach $69.25 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View analysts' price targets for Relmada Therapeutics.

Has Relmada Therapeutics been receiving favorable news coverage?

Media coverage about RLMD stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Relmada Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Relmada Therapeutics.

Who are some of Relmada Therapeutics' key competitors?

What other stocks do shareholders of Relmada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relmada Therapeutics investors own include Verizon Communications (VZ), Alteryx (AYX), Enterprise Products Partners (EPD), Vertex Pharmaceuticals (VRTX), Advanced Micro Devices (AMD), Intel (INTC), Okta (OKTA), Energy Transfer LP Unit (ET), IBM (IBM) and JPMorgan Chase & Co. (JPM).

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the following people:
  • Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO & Director (Age 60, Pay $678.23k)
  • Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, Chief Financial Officer (Age 56, Pay $33.5k)
  • Mr. Charles S. Ence CPA, M.B.A., Chief Accounting & Compliance Officer (Age 55, Pay $290.36k)
  • Ms. Gina DiGuglielmo, VP & Head of Clinical Operations
  • Dr. Thomas C. Wessel, Exec. VP and Head of R&D (Age 64)

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD."

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $42.33.

How big of a company is Relmada Therapeutics?

Relmada Therapeutics has a market capitalization of $643.33 million. Relmada Therapeutics employs 6 workers across the globe.

What is Relmada Therapeutics' official website?

The official website for Relmada Therapeutics is www.relmada.com.

How can I contact Relmada Therapeutics?

The company can be reached via phone at 646-876-3459.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.